These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 33621484)

  • 21. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
    Mittal A; Khattri A; Verma V
    PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
    Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ
    Cell Host Microbe; 2021 Mar; 29(3):477-488.e4. PubMed ID: 33535027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging plasticity of SARS-CoV-2.
    McCormick KD; Jacobs JL; Mellors JW
    Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
    [No Abstract]   [Full Text] [Related]  

  • 27. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
    Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
    Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
    Liu L; Iketani S; Guo Y; Chan JF; Wang M; Liu L; Luo Y; Chu H; Huang Y; Nair MS; Yu J; Chik KK; Yuen TT; Yoon C; To KK; Chen H; Yin MT; Sobieszczyk ME; Huang Y; Wang HH; Sheng Z; Yuen KY; Ho DD
    Nature; 2022 Feb; 602(7898):676-681. PubMed ID: 35016198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
    Nabel KG; Clark SA; Shankar S; Pan J; Clark LE; Yang P; Coscia A; McKay LGA; Varnum HH; Brusic V; Tolan NV; Zhou G; Desjardins M; Turbett SE; Kanjilal S; Sherman AC; Dighe A; LaRocque RC; Ryan ET; Tylek C; Cohen-Solal JF; Darcy AT; Tavella D; Clabbers A; Fan Y; Griffiths A; Correia IR; Seagal J; Baden LR; Charles RC; Abraham J
    Science; 2022 Jan; 375(6578):eabl6251. PubMed ID: 34855508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.
    Cai Y; Zhang J; Xiao T; Lavine CL; Rawson S; Peng H; Zhu H; Anand K; Tong P; Gautam A; Lu S; Sterling SM; Walsh RM; Rits-Volloch S; Lu J; Wesemann DR; Yang W; Seaman MS; Chen B
    Science; 2021 Aug; 373(6555):642-648. PubMed ID: 34168070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
    Lennerstrand J; Palanisamy N
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron.
    Hu J; Peng P; Cao X; Wu K; Chen J; Wang K; Tang N; Huang AL
    Cell Mol Immunol; 2022 Feb; 19(2):293-295. PubMed ID: 35017716
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why are some coronavirus variants more infectious?
    Mukherjee R; Satardekar R
    J Biosci; 2021; 46(4):. PubMed ID: 34785628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.
    Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO
    J Biol Chem; 2021; 296():100536. PubMed ID: 33716040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.